dalpiciclib + endocrine therapy (Hengrui Pharmaceutical)

Dalpiciclib (SHR6390) is an orally bioavailable, selective small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), developed by Jiangsu Hengrui Pharmaceuticals. It is designed to arrest the cell cycle in the G1 phase, thereby inhibiting the proliferation of cancer cells. In the context of the Fujian Cancer Hospital study, dalpiciclib is being evaluated in combination with standard-of-care endocrine therapies—including selective estrogen receptor modulators (tamoxifen) or aromatase inhibitors (anastrozole, letrozole, or exemestane)—as an adjuvant treatment for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early-stage breast cancer. The trial specifically investigates the efficacy and safety of different durations (2 vs. 3 years) and doses of dalpiciclib in this setting.

Brand names

Dawu

Other names

dalpiciclib + tamoxifendalpiciclib + anastrozoledalpiciclib + letrozoledalpiciclib + exemestane